Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Zumatek
AddedFeb 18, 2024
UpdatedJun 18, 2026
Zumatek

Zumatek

Angel

ZumaTek, Inc.: NC-based software firm innovating in 3D imaging tech for early breast cancer detection & treatment monitoring.

HQ
Chapel Hill, NC, US
Founded
2005
Overview
Compare
Fundraising
Employees

Zumatek, Inc., based in Chapel Hill, North Carolina, focuses on developing advanced 3D imaging technologies for early breast cancer detection and treatment monitoring. Their devices non-invasively detect chemical changes in cancer cells, aiding in the early intervention before tumors form or spread. Additionally, their technology can be integrated with biopsy or treatment devices, enhancing the effectiveness of radiation therapy and chemotherapy.

Since its incorporation in 2005, Zumatek has made significant strides in the medical imaging field, contributing to improved patient outcomes through early detection and precise monitoring. Their innovative approach has positioned them as a key player in the fight against breast cancer, leveraging cutting-edge technology to provide critical insights into cancer progression and treatment efficacy.

Zumatek - Similar Companies

Advanced Fpat Imaging logo

Advanced Fpat Imaging

Visiongate logo

Visiongate

visiongate3d.com

Vita Imaging logo

Vita Imaging

Lumedica logo

Lumedica

Bired Imaging logo

Bired Imaging

biredimaging.com

Imago Systems logo

Imago Systems

imagosystems.com

Kiyatec logo

Kiyatec

kiyatec.com

Zymeron logo

Zymeron

zymeron.com

Real Time Imaging Technologies logo

Real Time Imaging Technologies

O2M Technologies logo

O2M Technologies

Advanced Chemotherapy Technologies logo

Advanced Chemotherapy Technologies

Med-Tek logo

Med-Tek

med-tek.com

Radiosight logo

Radiosight

radiosight.com

Matrix-Bio logo

Matrix-Bio

VisExcell logo

VisExcell

Zumatek - Quick Facts

Who are Zumatek's competitors?

Companies similar to Zumatek include Advanced Fpat Imaging, Visiongate, Vita Imaging and Lumedica.

When was Zumatek founded?

Zumatek was founded in 2005.

Where is Zumatek's headquarters located?

Zumatek's headquarters is located in Chapel Hill, NC, US.

When was Zumatek's last funding round?

Zumatek's most recent funding round was for $150k (USD) in November 2010.

How much has Zumatek raised to-date?

As of Nov 23, 2010, Zumatek has raised a total of $150k (USD).

How many employees does Zumatek have?

Zumatek has 6 employees as of Feb 5, 2024.

Zumatek - Classification

Ownership
  • Private
Technology
  • AI
  • Analytics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medical Imaging
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software